| Bowen Shi,Jianlong Bu,Yanbo Wang,Lantao Chen,Shidong Xu. Elevated pretreatment plasma fibrinogen level is associated with metastasis of non-small cell lung cancer (NSCLC). Oncol Transl Med, 2020, 6: 200-207. |
| Elevated pretreatment plasma fibrinogen level is associated with metastasis of non-small cell lung cancer (NSCLC) |
| Received:May 19, 2020 Revised:October 16, 2020 |
| View Full Text View/Add Comment Download reader |
| KeyWord:fibrinogen; metastasis; NSCLC; tumor stage |
| Author Name | Affiliation | E-mail | | Bowen Shi | Department of Thoracic Surgery, Harbin Medical University Cancer Hospital | sbw1012@163.com | | Jianlong Bu | Department of Thoracic Surgery, Harbin Medical University Cancer Hospital | | | Yanbo Wang | Department of Thoracic Surgery, Harbin Medical University Cancer Hospital | | | Lantao Chen | Department of Thoracic Surgery, Harbin Medical University Cancer Hospital | | | Shidong Xu | Department of Thoracic Surgery, Harbin Medical University Cancer Hospital | |
|
| Hits: 7038 |
| Download times: 7919 |
| Abstract: |
| Objective The aim of this study was to investigate the correlation between pretreatment fibrinogen levels
and metastasis in non-small cell lung cancer (NSCLC).
Methods The study included 503 NSCLC patients with a clear pathological diagnosis and 168 patients
diagnosed with benign lung diseases by histological examination. Pretreatment plasma fibrinogen values
were quantified, and the relationship between plasma fibrinogen level and clinical variables comprising
tumor size, metastasis, and clinical stage was examined using Kruskal-Wallis test, Wilcoxon rank sum test,
and Chi-square test.
Results The median plasma fibrinogen values were statistically higher in NSCLC patients with metastasis
than patients with benign lung diseases and NSCLC patients without metastasis (Kruskal-Wallis test; P <
0.001). Plasma fibrinogen values were also significantly higher in advanced clinical stages (Wilcoxon rank
sum test; P < 0.001). A significant relationship was observed between elevated fibrinogen (> 2.974 g/L) and
metastasis, clinical stage, and tumor size (Chi-square test; P < 0.001).
Conclusion This correlation suggests that elevated pretreatment plasma fibrinogen levels can predict
metastasis and advanced tumor stage in NSCLC patients. |
| Close |
|
|
|